|
[1]SUZUKI D, SHIMIZU K, TOKUSHIGE K.Relative rise of serum Ig G4 levels after steroid therapy for autoimmune pancreatitis predicts the likelihood of relapse[J].Pancreas, 2018, 47 (4) :412-417.
|
|
[2]LEE HW, MOON SH, KIM MH, et al.Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis:Long-term follow-up results after steroid therapy with short-duration maintenance treatment[J].J Gastroenterol, 2018.[Epub ahead of print]
|
|
[3]HUBERS LM, VOS H, SCHUURMAN AR, et al.Annexin A11 is targeted by Ig G4 and Ig G1 autoantibodies in Ig G4-related disease[J].Gut, 2018, 67 (4) :728-735.
|
|
[4]OKAZAKI K, CHARI ST, FRULLONI L, et al.International consensus for the treatment of autoimmune pancreatitis[J].Pancreatology, 2017, 17 (1) :1-6.
|
|
[5]KUBOTA K, KAMISAWA T, OKAZAKI K, et al.Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis:A long-term Japanese multicenter analysis of 510 patients[J].J Gastroenterol, 2017, 52 (8) :955-964.
|
|
[6]KAMISAWA T, SHIMOSEGAWA T, OKAZAKI K, et al.Standard steroid treatment for autoimmune pancreatitis[J].Gut, 2009, 58 (11) :1504-1507.
|
|
[7]KHOSROSHAHI A, WALLACE ZS, CROWE JL, et al.International consensus guidance statement on themanagement and treatment of Ig G4-related disease[J].Arthritis Rheumatol, 2015, 67 (7) :1688-1699.
|
|
[8]WANG L, ZHANG P, WANG M, et al.Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in Ig G4-related disease:A prospective study of 215 patients[J].Arthritis Res Ther, 2018, 20 (1) :65.
|
|
[9]BRITO-ZERON P, KOSTOV B, BOSCH X, et al.Therapeutic approach to Ig G4-related disease:A systematic review[J].Medicine, 2016, 95 (26) :e4002.
|
|
[10] ZHANG PP, ZHANG W.Clinical, imaging, and pathological features of organ injuries in Ig G4-related diseases[J].Chin J Intern Med, 2016, 55 (8) :657-661. (in Chinese) 张盼盼, 张文.Ig G4相关性疾病脏器损伤的临床特点、影像学及病理特征[J].中华内科杂志, 2016, 55 (8) :657-661.
|
|
[11]BRITO-ZERON P, BOSCH X, RAMOS-CASALS M, et al.Ig G4-related disease:Advances in the diagnosis and treatment[J].Best Pract Res Clin Rheumatol, 2016, 30 (2) :261-278.
|
|
[12]AKIYAMA M, TAKEUCHI T.Ig G4-related disease:Beyond glucocorticoids[J].Drugs&Aging, 2018.[Epub ahead of print]
|
|
[13]SHEN RF, ZENG FD, SHI SJ.Research advances in pharmacological action and clinical application of azathioprine[J].China Pharmacist, 2013, 16 (9) :1409-1412. (in Chinese) 沈如飞, 曾繁典, 师少军.硫唑嘌呤的药理作用和临床应用研究进展[J].中国药师, 2013, 16 (9) :1409-1412.
|
|
[14]BOSCO JJ, SUAN D, VARIKATT W, et al.Extra-pancreatic manifestations of Ig G4-related systemic disease:A single-centre experience of treatment with combined immunosuppression[J].Intern Med J, 2013, 43 (4) :417-423.
|
|
[15]FRULLONI L, de PRETIS N, AMODIO A.Maintenance therapy in autoimmune pancreatitis:A weak light into the darkness[J].Ann Transl Med, 2017, 5 (17) :367.
|
|
[16]de PRETIS N, AMODIO A, BERNARDONI L, et al.Azathioprine maintenance therapy to prevent relapses in autoimmune pancreatitis[J].Clin Transl Gastroenterol, 2017, 8 (4) :e90.
|
|
[17]LEE YH, SONG GG.Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis:A Bayesian network meta-analysis of randomized controlled trials[J].Lupus, 2015, 24 (14) :1520-1528.
|
|
[18]ONG LM, HOOI LS, LIM TO, et al.Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis[J].Nephrology (Carlton, Vic) , 2005, 10 (5) :504-510.
|
|
[19]HART PA, ZEN Y, CHARI ST.Recent advances in autoimmune pancreatitis[J].Gastroenterology, 2015, 149 (1) :39-51.
|
|
[20]MANNION M, CRON RQ.Successful treatment of pediatric Ig G4related systemic disease with mycophenolate mofetil:C``ase report and a review of the pediatric autoimmune pancreatitis literature[J].Pediatr Rheumatol Online J, 2011, 9 (1) :1.
|
|
[21]MOSS HE, MEJICO LJ, de la ROZA G, et al.Ig G4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil[J].J Neurol Sci, 2012, 318 (1-2) :31-35.
|
|
[22]SISTIGU A, VIAUD S, CHAPUT N, et al.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design[J].Semin Immunopathol, 2011, 33 (4) :369-383.
|
|
[23]DAN D, FISCHER R, ADLER S, et al.Cyclophosphamide:As bad as its reputation?Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases[J].Swiss Med Wkly, 2014, 144:w14030.
|
|
[24]TELES KA, MEDEIROS-SOUZA P, LIMA FA, et al.Cyclophosphamide administration routine in autoimmune rheumatic diseases:A review[J].Rev Bras Reumatol Engl Ed, 2017, 57 (6) :596-604.
|
|
[25]ZHU LP, CUPPS TR, WHALEN G, et al.Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells[J].J Clin Invest, 1987, 79 (4) :1082-1090.
|
|
[26]YUNYUN F, YU C, PANPAN Z, et al.Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids[J].Sci Rep, 2017, 7 (1) :6195.
|
|
[27]DELLA-TORRE E, CAMPOCHIARO C, BOZZOLO EP, et al.Methotrexate for maintenance of remission in Ig G4-related disease[J].Rheumatology, 2015, 54 (10) :1934-1936.
|
|
[28]MORRIS RE, HUANG X, CAO W, et al.Leflunomide (HWA486) and its analog suppress T-and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury[J].Transplant Proc, 1995, 27 (1) :445-447.
|
|
[29]WANG Y, LI K, GAO D, et al.Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with Ig G4-related disease:A retrospective study and literature review[J].Intern Med J, 2017, 47 (6) :680-689.
|
|
[30]SCHWAIGER T, van den BRANDT C, FITZNER B, et al.Autoimmune pancreatitis in MRL/Mp mice is a T cell-mediated disease responsive to cyclosporine A and rapamycin treatment[J].Gut, 2014, 63 (3) :494-505.
|
|
[31]ZHANG YZ, ZHANG CX.Research progress of pharmacological effects and clinical efficacy of tacrolimus[J].Chin Hosp Pharm J, 2016, 36 (3) :241-244. (in Chinese) 张咏赞, 张翠欣.他克莫司药理作用及临床疗效的研究进展[J].中国医院药学杂志, 2016, 36 (3) :241-244.
|
|
[32]BUECHTER M, KLEIN CG, KLOETERS C, et al.Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with Ig G4-associated cholangitis[J].Z Gastroenterol, 2014, 52 (6) :564-568.
|
|
[33]SELEZNIK G, GRAF R.Alternatives to steroids?!Beneficial effects of immunosuppressant drugs in autoimmune pancreatitis[J].Gut, 2014, 63 (3) :376-377.
|
|
[34]ZHANG JL, HUANG F.Pharmacological action of hydroxychloroquine and its application in rheumatic diseases[J].Pharm J Chin PLA, 2000, 16 (2) :85-88. (in Chinese) 张江林, 黄烽.羟氯喹的药理作用及在风湿性疾病中的应用[J].解放军药学学报, 2000, 16 (2) :85-88.
|
|
[35]MUCKE HA.Iguratimod:A new disease-modifying antirheumatic drug[J].Drugs Today (Barc) , 2012, 48 (9) :577-586.
|
|
[36]XIAO W, GUO JP, LI C, et al.Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis[J].Pharmacogenomics, 2018, 19 (5) :383-392.
|
|
[37]MAJUMDER S, MOHAPATRA S, LENNON RJ, et al.Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease[J].Clin Gastroenterol Hepatol, 2018.[Epub ahead of print]
|
|
[38]WALLACE ZS, MATTOO H, MAHAJAN VS, et al.Predictors of disease relapse in Ig G4-related disease following rituximab[J].Rheumatology, 2016, 55 (6) :1000-1008.
|
|
[39]KAMISAWA T, OKAZAKI K.Diagnosis and treatment of Ig G4-related disease[J].Curr Top Microbiol Immunol, 2017, 401:19-33.
|
|
[40]CARRUTHERS MN, TOPAZIAN MD, KHOSROSHAHI A, et al.Rituximab for Ig G4-related disease:A prospective, open-label trial[J].Ann Rheum Dis, 2015, 74 (6) :1171-1177.
|
|
[41]STONE JH, CARRUTHERS MN, TOPAZIAN MD, et al.Response to:Is rituximab effective for Ig G4-related disease in the long term?Experience of cases treated with rituximab for 4 years'by Yamamoto et al[J].Ann Rheum Dis, 2015, 74 (8) :e47.
|
|
[42]PARK DH, KIM M, OH HB, et al.Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis[J].Gastroenterology, 2008, 134 (2) :440-446.
|
|
[43]KHOSROSHAHI A, STONE JH.Treatment approaches to Ig G4-related systemic disease[J].Curr Opin Rheumatol, 2011, 23 (1) :67-71.
|
|
[44]SATO Y, KOJIMA M, TAKATA K, et al.Multicentric Castleman's disease with abundant Ig G4-positive cells:A clinical and pathological analysis of six cases[J].J Clin Pathol, 2010, 63 (12) :1084-1089.
|
|
[45]YAMAMOTO M.New strategies for the treatment of Ig G4-related disease[J].Nihon Rinsho Meneki Gakkai Kaishi, 2016, 39 (6) :485-490.
|
DownLoad: